KCA Coordinator of work on molecularly targeted therapeutics, drug discovery, minimal residual disease detection, and molecular profiling
Prof Haber was appointed Executive Director of Children’s Cancer Institute Australia (CCIA) in 2003, having been a scientist at the Institute since its beginning in 1984. During the past 20 years, she has made a major contribution to Australia’s health and medical research effort in the field of child cancer.
In particular, she is known nationally and internationally for her research on delineating mechanisms of resistance to anti-cancer drugs in the treatment of neuroblastoma, and in developing new approaches to improving the outcome of children diagnosed with acute lymphoblastic leukaemia.
She has taken a leading role in pioneering high-throughput screening of chemical small molecule libraries for drug discovery in child cancer.
Prof Haber is the current President of the International Advances in Neuroblastoma Research Association. She was appointed a Member of the Order of Australia in 2007 for services to science, scientific education and the community. The following year, she was awarded an Honorary Doctorate by the UNSW for her service to the cancer research community.